Table 3 Characteristics of the 160 surgically treated patients with IE in Western Norway during 2016–2022, according to sex

EuroSCORE II

Mean, % (SD)

10.8 (15.4)

11.5 (14.2)

0.802

Time to surgery

Median, days (IQR)

25 (17–51)

21 (10–32)

0.043

Proportion of operated valves

Aortic valve, n (%)

17/75 (23)

102/263 (39)

0.001

Mitral valve, n (%)

12/41 (29)

19/62 (31)

0.881

Tricuspid valve, n (%)

6/19 (32)

6/39 (15)

0.153

Mortality

30-day, n (%)

2 (6)

1 (1)

0.599

90- day, n (%)

2 (6)

6 (5)

0.786

Overall, n (%)

11 (32)

27 (21)

0.085

Indications for surgery^a

Heart failure, n (%)

26 (76)

116 (92)

0.011

Unresolving bacteriemia, n (%)

17 (50)

66 (52)

0.805

Ongoing embolization, n (%)

5 (15)

14 (11)

0.565

Valvular ring abscess, n (%)

5 (15)

29 (23)

0.293

Re-do surgery on PVE

Number, n (%)

8 (24)

46 (37)

0.156

Surgery on the aortic valve and aorta ascendens^b, n (%)

17 (50)

102 (81)

< 0.001

Isolated aortic valve surgery, n (%)

13 (38)

81 (64)

0.005

Biological prosthesis, n (%)

11 (32)

65 (52)

0.042

Mechanical prosthesis, n (%)

2 (6)

16 (13)

0.366

Annuloplasty, n (%)

0

1 (1)

-

Combined valve/aorta ascendens, n (%)

5 (15)

29 (23)

0.284

Reconstruction aorta and root, n (%)

3 (9)

14 (11)

-

Biological prosthesis and root, n (%)

3 (9)

18 (14)

0.570

Mechanical prosthesis and root, n (%)

0

3 (2)

-

Surgery on the mitral valve³, n (%)

12 (35)

19 (15)

0.009

Biological prosthesis, n (%)

7 (21)

9 (7)

0.047

Mechanical prosthesis, n (%)

2 (6)

4 (3)

0.609

Annuloplasty, n (%)

3 (9)

5 (4)

0.369

Reconstruction, n (%)

1 (3)

5 (4)

-

Surgery on the tricuspid valve, n (%)

6 (18)

6 (5)

0.022

Biological prosthesis, n (%)

7 (21)

6 (5)

0.007

Annuloplasty, n (%)

1 (3)

0

-

Postoperative complications

Bleeding, n (%)

6 (18)

15 (12)

0.360

Temporary haemodialysis, n (%)

7 (21)

9 (7)

0.019

Severe infection^c, n (%)

2 (6)

9 (7)

0.797